AI3-17708

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 592111

CAS#: 6222-35-1

Description: AI3-17708 is a fragrance ingredient.

Chemical Structure

img
AI3-17708
CAS# 6222-35-1
Instruction

Theoretical Analysis

MedKoo Cat#: 592111
Name: AI3-17708
CAS#: 6222-35-1
Chemical Formula: C9H16O2
Exact Mass: 156.12
Molecular Weight: 156.230
Elemental Analysis: C, 69.19; H, 10.32; O, 20.48

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: AI3-17708; AI3 17708; AI317708

IUPAC/Chemical Name: Cyclohexyl propionate

InChi Key: MAMMVUWCKMOLSG-UHFFFAOYSA-N

InChi Code: InChI=1S/C9H16O2/c1-2-9(10)11-8-6-4-3-5-7-8/h8H,2-7H2,1H3

SMILES Code: CCC(OC1CCCCC1)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 156.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Api AM, Belsito D, Botelho D, Browne D, Bruze M, Burton GA Jr, Buschmann J, Dagli ML, Date M, Dekant W, Deodhar C, Francis M, Fryer AD, Joshi K, La Cava S, Lapczynski A, Liebler DC, O'Brien D, Parakhia R, Patel A, Penning TM, Ritacco G, Romine J, Salvito D, Schultz TW, Sipes IG, Thakkar Y, Theophilus EH, Tiethof AK, Tokura Y, Tsang S, Wahler J. RIFM fragrance ingredient safety assessment 4-(Isopropyl)cyclohexyl propionate, CAS Registry Number 63449-95-6. Food Chem Toxicol. 2017 Dec;110 Suppl 1:S704-S710. doi: 10.1016/j.fct.2017.10.046. Epub 2017 Oct 31. PubMed PMID: 29097119.

2: Maya-López M, Ruiz-Contreras HA, de Jesús Negrete-Ruíz M, Martínez-Sánchez JE, Benítez-Valenzuela J, Colín-González AL, Villeda-Hernández J, Sánchez-Chapul L, Parra-Cid C, Rangel-López E, Santamaría A. URB597 reduces biochemical, behavioral and morphological alterations in two neurotoxic models in rats. Biomed Pharmacother. 2017 Apr;88:745-753. doi: 10.1016/j.biopha.2017.01.116. Epub 2017 Jan 31. PubMed PMID: 28157650.

3: Shen SH, Yu N, Liu XY, Tan GW, Wang ZX. Gamma-glutamylcyclotransferase promotes the growth of human glioma cells by activating Notch-Akt signaling. Biochem Biophys Res Commun. 2016 Mar 18;471(4):616-20. doi: 10.1016/j.bbrc.2016.01.165. Epub 2016 Jan 30. PubMed PMID: 26828272.

4: Tanis KQ, Podtelezhnikov AA, Blackman SC, Hing J, Railkar RA, Lunceford J, Klappenbach JA, Wei B, Harman A, Camargo LM, Shah S, Finney EM, Hardwick JS, Loboda A, Watters J, Bergstrom DA, Demuth T, Herman GA, Strack PR, Iannone R. An accessible pharmacodynamic transcriptional biomarker for notch target engagement. Clin Pharmacol Ther. 2016 Apr;99(4):370-80. doi: 10.1002/cpt.335. Epub 2016 Feb 17. PubMed PMID: 26765077.

5: Chen X, Gong L, Ou R, Zheng Z, Chen J, Xie F, Huang X, Qiu J, Zhang W, Jiang Q, Yang Y, Zhu H, Shi Z, Yan X. Sequential combination therapy of ovarian cancer with cisplatin and γ-secretase inhibitor MK-0752. Gynecol Oncol. 2016 Mar;140(3):537-44. doi: 10.1016/j.ygyno.2015.12.011. Epub 2015 Dec 15. PubMed PMID: 26704638.

6: Gouveia-Figueira S, Karlsson J, Deplano A, Hashemian S, Svensson M, Fredriksson Sundbom M, Congiu C, Onnis V, Fowler CJ. Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor. PLoS One. 2015 Sep 25;10(9):e0139212. doi: 10.1371/journal.pone.0139212. eCollection 2015. PubMed PMID: 26406890; PubMed Central PMCID: PMC4583449.

7: Piha-Paul SA, Munster PN, Hollebecque A, Argilés G, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A, Gupta S. Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours. Eur J Cancer. 2015 Sep;51(14):1865-73. doi: 10.1016/j.ejca.2015.06.115. Epub 2015 Jul 18. PubMed PMID: 26199039; PubMed Central PMCID: PMC5693226.

8: Hoffman LM, Fouladi M, Olson J, Daryani VM, Stewart CF, Wetmore C, Kocak M, Onar-Thomas A, Wagner L, Gururangan S, Packer RJ, Blaney SM, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ. Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. Childs Nerv Syst. 2015 Aug;31(8):1283-9. doi: 10.1007/s00381-015-2725-3. Epub 2015 May 1. PubMed PMID: 25930724; PubMed Central PMCID: PMC4681692.

9: Fantoni DT, Ida KK, de Almeida TI, Ambrósio AM. A comparison of pre and post-operative vedaprofen with ketoprofen for pain control in dogs. BMC Vet Res. 2015 Feb 7;11:24. doi: 10.1186/s12917-015-0338-4. PubMed PMID: 25880775; PubMed Central PMCID: PMC4324799.

10: Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer. 2014 Nov 11;111(10):1932-44. doi: 10.1038/bjc.2014.497. Epub 2014 Oct 7. PubMed PMID: 25290091; PubMed Central PMCID: PMC4229637.

11: Zhang S, Chung WC, Miele L, Xu K. Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer. Cancer Biol Ther. 2014 May;15(5):633-42. doi: 10.4161/cbt.28180. Epub 2014 Feb 20. PubMed PMID: 24556651; PubMed Central PMCID: PMC4026086.

12: Schott AF, Landis MD, Dontu G, Griffith KA, Layman RM, Krop I, Paskett LA, Wong H, Dobrolecki LE, Lewis MT, Froehlich AM, Paranilam J, Hayes DF, Wicha MS, Chang JC. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res. 2013 Mar 15;19(6):1512-24. doi: 10.1158/1078-0432.CCR-11-3326. Epub 2013 Jan 22. PubMed PMID: 23340294; PubMed Central PMCID: PMC3602220.

13: Gounder MM, Schwartz GK. Moving forward one Notch at a time. J Clin Oncol. 2012 Jul 1;30(19):2291-3. doi: 10.1200/JCO.2012.42.3277. Epub 2012 May 7. PubMed PMID: 22564999.

14: Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, Butowski N, Groves MD, Kesari S, Freedman SJ, Blackman S, Watters J, Loboda A, Podtelezhnikov A, Lunceford J, Chen C, Giannotti M, Hing J, Beckman R, Lorusso P. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol. 2012 Jul 1;30(19):2307-13. doi: 10.1200/JCO.2011.39.1540. Epub 2012 Apr 30. PubMed PMID: 22547604.

15: Whitehead J, Thygesen H, Jaki T, Davies S, Halford S, Turner H, Cook N, Jodrell D. A novel Phase I/IIa design for early phase oncology studies and its application in the evaluation of MK-0752 in pancreatic cancer. Stat Med. 2012 Aug 15;31(18):1931-43. doi: 10.1002/sim.5331. Epub 2012 Apr 11. PubMed PMID: 22495759.

16: Ishihara M, Fujita K, Ito H, Matsuda T, Yatsukawa Y, Nakamura M, Sakai T, Nemoto S. [Determination of vedaprofen in livestock products and seafoods by liquid chromatography-tandem mass spectrometry]. Shokuhin Eiseigaku Zasshi. 2011;52(5):304-8. Japanese. PubMed PMID: 22200750.

17: Fouladi M, Stewart CF, Olson J, Wagner LM, Onar-Thomas A, Kocak M, Packer RJ, Goldman S, Gururangan S, Gajjar A, Demuth T, Kun LE, Boyett JM, Gilbertson RJ. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Clin Oncol. 2011 Sep 10;29(26):3529-34. doi: 10.1200/JCO.2011.35.7806. Epub 2011 Aug 8. PubMed PMID: 21825264; PubMed Central PMCID: PMC3179253.

18: Khwanjai V, Chuthatep S, Durongphongtorn S, Yibchok-Anun S. Evaluating the effects of 14-day oral vedaprofen and tolfenamic acid treatment on renal function, hematological and biochemical profiles in healthy cats. J Vet Pharmacol Ther. 2012 Feb;35(1):13-8. doi: 10.1111/j.1365-2885.2011.01282.x. Epub 2011 Mar 11. PubMed PMID: 21392038.

19: Brondani JT, Luna SP, Padovani CR. Refinement and initial validation of a multidimensional composite scale for use in assessing acute postoperative pain in cats. Am J Vet Res. 2011 Feb;72(2):174-83. doi: 10.2460/ajvr.72.2.174. PubMed PMID: 21281191.

20: Bai F, Tagen M, Colotta C, Miller L, Fouladi M, Stewart CF. Determination of the gamma-secretase inhibitor MK-0752 in human plasma by online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Sep 1;878(25):2348-52. doi: 10.1016/j.jchromb.2010.07.019. Epub 2010 Jul 30. Erratum in: J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Nov 1;908:161. PubMed PMID: 20702149; PubMed Central PMCID: PMC2926936.